Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8213 results

  1. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]

    Awaiting development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. DV7103 for treating cystinuria in people 6 months and over [TSID10438]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation